Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myeloid leukemia 239Pu-treated mice

V Svoboda, D Bubeníková, Z Kotasková

    Journal of Cancer Research and Clinical Oncology
    |January 1, 1981
    PubMed
    Summary

    Plutonium-239 exposure did not significantly alter myeloid leukemia incidence in mice. However, plutonium contamination caused the disease to appear earlier and at a younger age in affected animals.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Real-Time Dynamics of the Formation of Hydrated Electrons upon Irradiation of Water Clusters with Extreme Ultraviolet Light.

    Physical review letters·2019
    Same author

    Low cost alternative of high speed visible light camera for tokamak experiments.

    The Review of scientific instruments·2012
    Same author

    Late complications after radiotherapy for prostate cancer.

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2012
    Same author

    Tumour inhibitory effects of plasmid DNA.

    Oncology reports·2011
    Same author

    Kinetics and function of peritoneal-exudate cells during local IL-2 gene-therapy of cancer.

    International journal of oncology·2011
    Same author

    Tumour vaccines expressing IL-2, CD80, and IL-2 plus CD80 gene.

    International journal of oncology·2011

    Area of Science:

    • Toxicology
    • Radiobiology
    • Oncology

    Background:

    • Investigating the long-term health effects of internal radionuclide exposure is crucial for understanding radiation-induced diseases.
    • Plutonium-239 (Pu) is a significant internal emitter with known carcinogenic potential.
    • Myeloid leukemia is a serious hematological malignancy that can be influenced by environmental factors.

    Purpose of the Study:

    • To determine the incidence of myeloid leukemia in mice following intravenous administration of Plutonium-239 (Pu).
    • To compare the occurrence and onset of myeloid leukemia in Pu-treated mice versus control groups.
    • To analyze the impact of Pu contamination on the age of disease onset and survival rates.

    Main Methods:

    • Intravenous injection of 180 kBq 239Pu/kg into 79 female ICR-SPF mice.
    • Comparison with a control group of 70 female ICR-SPF mice.
    • Histological and cytologic examination of bone marrow, spleen, liver, peripheral blood, and other tissues in moribund animals for disease diagnosis.

    Main Results:

    • Myeloid leukemia incidence was 27.8% in plutonium-treated mice (22/79) and 24.3% in controls (17/70).
    • Mean survival for diseased animals was significantly shorter in the plutonium group (459 ± 19 days) compared to controls (559 ± 24 days).
    • Plutonium contamination led to an earlier onset of myeloid leukemia, shifting incidence towards younger ages.

    Conclusions:

    • While Plutonium-239 (Pu) did not drastically increase overall myeloid leukemia incidence in this mouse model, it significantly accelerated disease onset.
    • The findings highlight the importance of internal alpha-emitter exposure in accelerating the development of radiation-related cancers.
    • Further research into the mechanisms of accelerated carcinogenesis by internal emitters is warranted.

    Related Experiment Videos